Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.
d'Oiron R, Volot F, Reynaud J, Peerlinck K, Goudemand J, Guérois C, Rothschild C, Chambost H, Borel-Derlon A, Roussel-Robert V, Marquès-Verdier A, Lienhart A, Berthier AM, Moreau P, Lambert T; MHAI Study Group. d'Oiron R, et al. Among authors: goudemand j. Semin Hematol. 2006 Jan;43(1 Suppl 1):S3-9. doi: 10.1053/j.seminhematol.2005.11.002. Semin Hematol. 2006. PMID: 16427382
French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance.
Rothschild C, Laurian Y, Satre EP, Borel Derlon A, Chambost H, Moreau P, Goudemand J, Parquet A, Peynet J, Vicariot M, Beurrier P, Claeyssens S, Durin A, Faradji A, Fressinaud E, Gaillard S, Guérin V, Guérois C, Pernod G, Pouzol P, Schved JF, Gazengel C. Rothschild C, et al. Among authors: goudemand j. Thromb Haemost. 1998 Nov;80(5):779-83. Thromb Haemost. 1998. PMID: 9843171
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM. Borel-Derlon A, et al. Among authors: goudemand j. J Thromb Haemost. 2007 Jun;5(6):1115-24. doi: 10.1111/j.1538-7836.2007.02562.x. J Thromb Haemost. 2007. PMID: 17403090 Free article. Clinical Trial.
Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk?
Giansily-Blaizot M, Verdier R, Biron-Adréani C, Schved JF, Bertrand MA, Borg JY, Le Cam-Duchez V, Briquel ME, Chambost H, Pouymayou K, Dutrillaux F, Favier R, Martin-Toutain I, Verdy E, Gay V, Goudemand J, Navarro R, Durin A, d'Oiron R, Lambert T, Pernod G, Barrot C, Peynet J, Bastenaire B, Sie P, Stieltjes N, Torchet MF, de Moerloose P; Study group of FVII deficiency. Giansily-Blaizot M, et al. Among authors: goudemand j. Haematologica. 2004 Jun;89(6):704-9. Haematologica. 2004. PMID: 15194538
Hepatitis A in French hemophiliacs.
Goudemand J, Parquet A, d'Oiron R, Stieltjes N, Guérois C, Fonlupt J, Alcalay M, Négrier C, Cazenave JP, Briquel ME, et al. Goudemand J, et al. Vox Sang. 1994;67 Suppl 1:9-12; discussion 13. Vox Sang. 1994. PMID: 8091745
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods.
Goudemand J, Scharrer I, Berntorp E, Lee CA, Borel-Derlon A, Stieltjes N, Caron C, Scherrmann JM, Bridey F, Tellier Z, Federici AB, Mannucci PM. Goudemand J, et al. J Thromb Haemost. 2005 Oct;3(10):2219-27. doi: 10.1111/j.1538-7836.2005.01435.x. J Thromb Haemost. 2005. PMID: 16194199 Free article. Clinical Trial.
Haemophilic arthropathy from A to Z. Introduction.
Négrier C, Goudemand J, Lambert T. Négrier C, et al. Among authors: goudemand j. Haemophilia. 2008 Jul;14 Suppl 4:1-2. doi: 10.1111/j.1365-2516.2008.01731.x. Haemophilia. 2008. PMID: 18494685 No abstract available.
220 results